GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Total Long-Term Liabilities

Evaxion Biotech AS (Evaxion Biotech AS) Total Long-Term Liabilities : $10.54 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Evaxion Biotech AS's Total Long-Term Liabilities for the quarter that ended in Dec. 2023 was $10.54 Mil.

Evaxion Biotech AS Total Long-Term Liabilities Historical Data

The historical data trend for Evaxion Biotech AS's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS Total Long-Term Liabilities Chart

Evaxion Biotech AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Long-Term Liabilities
Get a 7-Day Free Trial - - 3.40 9.96 10.54

Evaxion Biotech AS Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.96 13.91 10.17 14.68 10.54

Evaxion Biotech AS Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Evaxion Biotech AS Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS (Evaxion Biotech AS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Total Long-Term Liabilities
Comparable Companies
NLTX NXTC INAB LVTX LUMO ELDN PMN PTN MAIA LTRN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970
Website
https://www.evaxion-biotech.com
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.